{"disease":{"id":"active-rheumatoid-arthritis","name":"Active Rheumatoid Arthritis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"upadacitinib","indication_name":"Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"tnf-inhibitor","indication_name":"Active Rheumatoid Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Rheumatoid Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Rheumatoid Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Rheumatoid Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Rheumatoid Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Rheumatoid Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Rheumatoid Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Rheumatoid Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Rheumatoid Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Active Rheumatoid Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Rheumatoid Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":12,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04402086","title":"Rheumatology Patient Registry and Biorepository","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT06048224","title":"Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":669,"lead_sponsor_name":"Zhejiang Hisun Pharmaceutical Co. Ltd.","has_results":false},{"nct_id":"NCT03599986","title":"Clinical Efficacy and Safety of Leflunomide in Egyptian Patients With Active Rheumatoid Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":398,"lead_sponsor_name":"Eva Pharma","has_results":true},{"nct_id":"NCT03522415","title":"Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":275,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT06456489","title":"Pulse Steroid Injection in Refractory Rheumatoid Arthritis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":268,"lead_sponsor_name":"Sohag University","has_results":false},{"nct_id":"NCT06570798","title":"A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04876781","title":"Korean Post-marketing Surveillance for Xeljanz XR","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06738719","title":"A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":192,"lead_sponsor_name":"Celltrion","has_results":false},{"nct_id":"NCT07409103","title":"A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":180,"lead_sponsor_name":"Elevara Medicines Limited","has_results":false},{"nct_id":"NCT03172325","title":"Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Cinnagen","has_results":true},{"nct_id":"NCT04751396","title":"Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors","phase":"","overall_status":"RECRUITING","enrollment_count":125,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03357471","title":"Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"UCB Biopharma S.P.R.L.","has_results":true},{"nct_id":"NCT03346590","title":"Evolution of Total Energy Expenditure and Its Various Components in Active Rheumatoid Arthritis (RA)Treated With Anti-TNF Agents and Comparison With Healthy Subjects","phase":"NA","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT04472481","title":"Vitamin D Effect in Rheumatoid Arthritis.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Tanta University","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}